The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.00
Bid: 14.50
Ask: 15.50
Change: 0.00 (0.00%)
Spread: 1.00 (6.897%)
Open: 15.25
High: 15.25
Low: 14.75
Prev. Close: 15.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Parsortix Regulatory Approval Update

7 May 2013 07:00

RNS Number : 0281E
Angle PLC
07 May 2013
 



For immediate release

 

7 May 2013

 

ANGLE plc

("ANGLE" or "the Company")

 

PARSORTIX REGULATORY APPROVAL UPDATE

 

 

ANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce the appointment of a specialist regulatory company, Medical Device Management (MDM), to manage the process of obtaining regulatory authorisations for the clinical use of the Parsortix cell separation system.

 

MDM is focused entirely on the medical devices sector and has expertise worldwide in quality assurance systems, regulatory submissions and compliance. Its clients range from small innovative companies to international medical devices businesses.

 

In the European Union (EU), marketing authorisation will be via a CE Mark, which will give approval for clinical sales throughout the EU. In the US, the process requires the submission of a 510(k) application to the FDA. Authorisation under 510(k) will allow the Company to make the product available throughout the US for use in treating patients.

 

MDM's initial analysis has confirmed ANGLE's expectation of securing regulatory authorisation in the EU by the end of the current calendar year and making a regulatory submission to the FDA in the US in early 2014.

 

Although ANGLE has not yet started to market Parsortix, there has been a stream of potential users expressing interest in the product, particularly in its harvesting capability. These include major hospitals, leading research groups and several commercial companies. Geographically, interest has come from across the UK as well as several international locations including the US, Canada and Australia.

 

 

ANGLE's Founder and Chief Executive, Andrew Newland, commented:

"We are very pleased to have put in place a plan for securing regulatory authorisations in Europe and the United States. MDM are experts in this field and it is reassuring that they have expressed confidence in our ability to secure the authorisations needed to enter the multi-billion dollar market for the clinical use of our cell separating technology."

 

 

 

 

For further information:

 

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Cenkos Securities

Stephen Keys, Adrian Hargrave (Nominated adviser)

Andy Roberts, Christian Hobart (Sales)

 

020 7397 8900

Buchanan

Mark Court, Fiona Henson, Sophie Cowles

020 7466 5000

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEXLFBXEFLBBD
Date   Source Headline
29th Apr 20144:30 pmRNSHoldings in Company
8th Apr 20147:00 amRNSIntellectual Property Update
24th Mar 20147:00 amRNSAppointment of Scientific Adviser
17th Mar 20147:00 amRNSParsortix FDA Submission
24th Feb 20147:00 amRNSUse of Parsortix System with Liver Cancer Patients
18th Feb 20147:00 amRNSParsortix Launch at Circulate Conference in Berlin
30th Jan 20147:00 amRNSInterim Results
13th Jan 20147:00 amRNSCambridge Parsortix Laboratory
10th Jan 20147:00 amRNSNotification of Interim Results and Webcast
7th Jan 20147:00 amRNSAppointment of Scientific Adviser
17th Dec 20137:00 amRNSCE Mark Authorisation
13th Dec 20137:00 amRNSRaises £6.2m from Sale of Geomerics
31st Oct 20133:31 pmRNSResult of 2013 Annual General Meeting
9th Oct 20137:00 amRNSAnnual Report and Accounts and Notice of AGM
31st Jul 20137:00 amRNSPreliminary Results
25th Jul 20137:00 amRNSPositive Evaluation of Parsortix System
19th Jul 20137:00 amRNSNotification of Preliminary Results and Webcast
8th Jul 20137:00 amRNSParsortix Colorectal Cancer Validation
29th May 20137:00 amRNSDirector's Share Transfer
28th May 20137:00 amRNSParsortix Manufacturer Appointed
13th May 20137:00 amRNSPARSORTIX CELL HARVESTING
7th May 20137:00 amRNSParsortix Regulatory Approval Update
28th Feb 20137:00 amRNSParsortix Research Product Launch
15th Feb 201310:56 amRNSDirector's share transfer
31st Jan 20137:01 amRNSFundraising and Director's Dealings
31st Jan 20137:00 amRNSInterim Results
16th Jan 20137:00 amRNSNotification of Interim Results and Webcast
14th Jan 20137:00 amRNSParsortix Cell Recovery
7th Jan 20137:00 amRNSAppointment of NED
18th Dec 20127:00 amRNSParsortix Released to Research Partners
10th Dec 20127:00 amRNSBUSINESS UPDATE
18th Oct 20127:00 amRNSAppointment of Scientific Advisers
17th Oct 20123:45 pmRNSHolding(s) in the Company
11th Oct 20123:39 pmRNSResult of 2012 Annual General Meeting
3rd Sep 20127:00 amRNSIncreased Fundraising
1st Aug 20127:00 amRNSIncreased Fundraising
26th Jul 20127:01 amRNSFundraising
26th Jul 20127:00 amRNSPreliminary Results
24th Jul 20127:00 amRNSNotice of Preliminary Results and Conference Call
27th Jun 20127:00 amRNSOffer Unconditional for Novocellus' Partner Origio
7th Jun 20127:00 amRNSUpdate Re Novocellus' Partner ORIGIO A/S
16th May 20127:00 amRNSGeomerics Milestone Payment
30th Apr 20127:00 amRNSParsortix Design Breakthrough
26th Apr 20127:00 amRNSLaunches New Corporate Website
23rd Apr 20127:00 amRNSParsortix Update for Breast Cancer
17th Apr 20127:00 amRNSParsortix Validation for Ovarian Cancer
11th Apr 20127:00 amRNSNovocellus Embryosure® Trial Started
26th Mar 20127:00 amRNSGeomerics Update
15th Mar 20127:00 amRNSParsortix Validation for Colon Cancer
7th Mar 20128:00 amRNSHolding(s) in the Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.